Final Evidence Report and Meeting Summary

PDF cover

Newest Treatments for Hepatitis C: Final Report

This final report incorporates public comments received on a draft version. This assessment addresses the following questions: 1) among patients with genotype 1, what is the comparative clinical effectiveness of combinations of two or more DAAs compared to each other as well as to single DAA therapy used in combination with interferon and ribavirin; and 2) what is the comparative value of the new therapies, including analysis of their care value at the patient level and of their potential health system value when budget impact is also taken into consideration.


View All Materials on this Topic or Go Back to View More Materials